Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open-label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab, and Other Anti-Cancer Therapies in Patients With Select Locally Advanced or Metastatic Solid Tumor Malignancies

Trial Profile

A Phase 1/2, Open-label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab, and Other Anti-Cancer Therapies in Patients With Select Locally Advanced or Metastatic Solid Tumor Malignancies

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bempegaldesleukin (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Carboplatin; Cisplatin; Eribulin; Paclitaxel; Pemetrexed
  • Indications Advanced breast cancer; Bladder cancer; Carcinoma; Colorectal cancer; HER2 positive breast cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Triple negative breast cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PIVOT; PIVOT-02; PIVOT-04
  • Sponsors Nektar Therapeutics
  • Most Recent Events

    • 26 Sep 2022 Results assessing immunostimulatory bempegaldesleukin (BEMPEG) plus nivolumab in patients with advanced/metastatic urothelial carcinoma, published in the European Urology.
    • 22 Jun 2022 Status changed from active, no longer recruiting to completed.
    • 20 May 2022 This trial has been completed in Belgium according to European Clinical Trials Database record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top